Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?

Hertzel Salman, Michael Bergman, Naava Blumberger, Meir Djaldetti, Hanna Bessler

Research output: Contribution to journalArticlepeer-review


The aim of the study was to examine the effect of androgen deprivation drugs, i.e. leuprolide and bicalutamide on the immune cross-talk between human peripheral blood mononuclear cells (PBMC) and cells from PC-3 and LNCaP human prostate cancer lines. PBMC, PC-3 and LNCaP were separately incubated without and with two androgen-deprivation drugs, i.e. leuprolide and bicalutamide, and the secretion of IL-1β, IL-6, IL-1ra and IL-10 was examined. In addition, the effect of both drugs on the production of those cytokines was carried out after 24hours incubation of PBMC with both types of cancer cells. Leuprolide or bicalutamide did not affect the production of the cytokines by PBMC or by the prostate cancer cells from the two lines. Incubation of PBMC with PC-3 or LNCaP cells caused increased production of IL-1β, IL-6 and IL-10 as compared with PBMC incubated without malignant cells. While 10-7M and 10-8M of leuprolide caused a decreased secretion of IL-1β by PBMC previously incubated with prostate cancer cells without the drug, bicalutamide did not affect this PBMC activity at any drug concentration. This observation suggests the existence of an additional mechanism explaining the effect of androgen deprivation therapy in prostate cancer patients.

Original languageEnglish
Pages (from-to)21-24
Number of pages4
JournalBiomedicine and Pharmacotherapy
Issue number1
StatePublished - Feb 2014


  • Bicalutamide
  • Inflammatory cytokines
  • LHRH agonist
  • Leuprolide
  • Mononuclear cells
  • PC-3 and LNCaP
  • Prostate cancer cells


Dive into the research topics of 'Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?'. Together they form a unique fingerprint.

Cite this